Entrada Therapeutics, Inc. (TRDA)

NASDAQ: TRDA · Real-Time Price · USD
17.93
+0.16 (0.90%)
Nov 20, 2024, 4:00 PM EST - Market closed
0.90%
Market Cap 634.82M
Revenue (ttm) 215.23M
Net Income (ttm) 54.95M
Shares Out 35.41M
EPS (ttm) 1.55
PE Ratio 11.56
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 64,565
Open 17.72
Previous Close 17.77
Day's Range 17.52 - 17.94
52-Week Range 10.75 - 20.49
Beta -0.27
Analysts Strong Buy
Price Target 23.33 (+30.12%)
Earnings Date Nov 5, 2024

About TRDA

Entrada Therapeutics, Inc., a clinical-stage biotechnology company, develops endosomal escape vehicle (EEV) therapeutics for the treatment of multiple neuromuscular diseases. Its EEV platform develops a portfolio of oligonucleotide, antibody, and enzyme-based programs. Its therapeutic candidates, which include ENTR-601-44, which is in Phase I clinical trial for the treatment of Duchenne muscular dystrophy; and ENTR-701, which is in Phase 1/2 clinical trial for the treatment of myotonic dystrophy type 1. The company also offers ENTR-601-45 and E... [Read more]

Industry Biotechnology
Sector Healthcare
IPO Date Oct 29, 2021
Employees 159
Stock Exchange NASDAQ
Ticker Symbol TRDA
Full Company Profile

Financial Performance

Financial Statements

Analyst Forecast

According to 3 analysts, the average rating for TRDA stock is "Strong Buy." The 12-month stock price forecast is $23.33, which is an increase of 30.12% from the latest price.

Price Target
$23.33
(30.12% upside)
Analyst Consensus: Strong Buy
Stock Forecasts

News

Entrada Therapeutics Presents New Data Supporting its Expanding Duchenne Franchise at the 29th Annual Congress of the World Muscle Society

– Additional positive data from the Company's completed Phase 1 clinical trial evaluating ENTR-601-44 reinforces its safety profile and supports the planned Q4 2024 global regulatory filings for a Pha...

6 weeks ago - GlobeNewsWire

Entrada Therapeutics Promotes Natarajan Sethuraman, PhD, to President of Research and Development

BOSTON, Sept. 24, 2024 (GLOBE NEWSWIRE) -- Entrada Therapeutics, Inc. (Nasdaq: TRDA) is a clinical-stage biopharmaceutical company aiming to transform the lives of patients by establishing intracellul...

2 months ago - GlobeNewsWire

āshibio Announces Appointment of Dipal Doshi, CEO of Entrada Therapeutics, to its Board of Directors

BRISBANE, Calif.--(BUSINESS WIRE)--āshibio, a privately held, clinical-stage biotechnology company developing novel therapeutics for the treatment of bone and connective tissue disorders, today announ...

2 months ago - Business Wire

Entrada Therapeutics Announces Recipients of Second Annual Diversity, Representation, Equity and Advocacy MatterS (DREAMS) Grant Program

- Second annual DREAMS Grant Program awards $25,000 each to three U.S.-based non-profit organizations working to achieve greater equality for those living with Duchenne - - Announced in celebration of...

2 months ago - GlobeNewsWire

Entrada Therapeutics Announces $100 Million Registered Direct Offering

– The offering was led by a U.S.-based healthcare focused investor, two global mutual funds and Janus Henderson Investors, a global asset management firm – – The offering was led by a U.S.-based healt...

5 months ago - GlobeNewsWire

Entrada Therapeutics Reports Positive Preliminary Data in Healthy Volunteers from Phase 1 ENTR-601-44-101 Trial for Duchenne Muscular Dystrophy

– ENTR-601-44 was well-tolerated in healthy volunteers with no serious adverse events, no drug-related adverse events and no clinically significant changes or trends noted in vital signs, ECGs, physic...

5 months ago - GlobeNewsWire

Entrada Therapeutics to Present at Goldman Sachs 45th Annual Global Healthcare Conference

BOSTON, June 03, 2024 (GLOBE NEWSWIRE) -- Entrada Therapeutics, Inc. (Nasdaq: TRDA) is a clinical-stage biopharmaceutical company aiming to transform the lives of patients by establishing a new class ...

6 months ago - GlobeNewsWire

Entrada Therapeutics to Present at H.C. Wainwright 2nd Annual BioConnect Investor Conference at NASDAQ

BOSTON, May 16, 2024 (GLOBE NEWSWIRE) -- Entrada Therapeutics, Inc. (Nasdaq: TRDA) is a clinical-stage biopharmaceutical company aiming to transform the lives of patients by establishing a new class o...

6 months ago - GlobeNewsWire

Entrada Therapeutics Reports First Quarter 2024 Financial Results

– Initiated dosing of the fourth and final cohort of Phase 1 clinical trial of ENTR-601-44 for the potential treatment of DMD with data readout on track for October of 2024 –

7 months ago - GlobeNewsWire

Entrada Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results

– Cash runway extended through the second quarter of 2026 – – $352 million in cash, cash equivalents and marketable securities as of December 31, 2023 – – Completed dosing for third cohort of Phase 1 ...

9 months ago - GlobeNewsWire

Entrada Therapeutics to Present at Upcoming Investor Conferences

BOSTON, Feb. 07, 2024 (GLOBE NEWSWIRE) -- Entrada Therapeutics, Inc. (Nasdaq: TRDA), a clinical-stage biopharmaceutical company aiming to transform the lives of patients by establishing intracellular ...

10 months ago - GlobeNewsWire

Entrada Therapeutics Announces Updates on ENTR-601-44 in Duchenne Muscular Dystrophy

– Company completes dosing of first and second cohorts in Phase 1 clinical trial, ENTR-601-44-101 – – ENTR-601-44 clinical development program remains on track with data readout expected in second hal...

1 year ago - GlobeNewsWire

Entrada Therapeutics Announces First Participant Dosed in its Phase 1 Clinical Trial of ENTR-601-44 for the Potential Treatment of Duchenne Muscular Dystrophy

– Initiation of Phase 1 clinical trial marks Entrada's transition into a clinical company – – Data anticipated in the second half of 2024 – BOSTON, Sept. 21, 2023 (GLOBE NEWSWIRE) -- Entrada Therapeut...

1 year ago - GlobeNewsWire

Entrada Therapeutics Appoints Gina Chapman to its Board of Directors

BOSTON, Aug. 10, 2023 (GLOBE NEWSWIRE) -- Entrada Therapeutics, Inc. (Nasdaq: TRDA), a biopharmaceutical company aiming to transform the lives of patients by establishing intracellular Endosomal Escap...

1 year ago - GlobeNewsWire

Entrada Therapeutics Reports Second Quarter 2023 Financial Results

– On track to dose first participant in ENTR-601-44 Phase 1 clinical trial in the United Kingdom in September 2023 –

1 year ago - GlobeNewsWire

Entrada Therapeutics: Early Stage But Interesting

Entrada Therapeutics is developing endosomal escape vehicles (EEV) to deliver oligonucleotides for neuromuscular diseases. Despite having no clinical data, the company has a market cap of nearly $600m...

1 year ago - Seeking Alpha

Entrada Therapeutics to Present at Goldman Sachs 44th Annual Global Healthcare Conference

BOSTON, Mass., June 06, 2023 (GLOBE NEWSWIRE) -- Entrada Therapeutics, Inc. (Nasdaq: TRDA), a biopharmaceutical company aiming to transform the lives of patients by establishing intracellular Endosoma...

1 year ago - GlobeNewsWire

Entrada Therapeutics Reports First Quarter 2023 Financial Results

- $412 million in cash, cash equivalents and marketable securities as of March 31, 2023 - - Cash runway into the second half of 2025 -

1 year ago - GlobeNewsWire

Entrada Therapeutics Appoints Dr. Bernhardt Zeiher to its Board of Directors

BOSTON, April 04, 2023 (GLOBE NEWSWIRE) -- Entrada Therapeutics, Inc. (Nasdaq: TRDA), a biopharmaceutical company aiming to transform the lives of patients by establishing intracellular Endosomal Esca...

1 year ago - GlobeNewsWire

Entrada Therapeutics to Participate in Guggenheim Genomic Medicines and Rare Disease Conference

BOSTON, March 29, 2023 (GLOBE NEWSWIRE) -- Entrada Therapeutics, Inc. (Nasdaq: TRDA), a biopharmaceutical company aiming to transform the lives of patients by establishing intracellular Endosomal Esca...

1 year ago - GlobeNewsWire

Entrada Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results

- Established a transformative collaboration with Vertex to discover and develop intracellular Endosomal Escape Vehicle-therapeutics for myotonic dystrophy type 1 -

1 year ago - GlobeNewsWire

Entrada Therapeutics to Participate in Cowen 43rd Annual Health Care Conference

BOSTON, Feb. 27, 2023 (GLOBE NEWSWIRE) -- Entrada Therapeutics, Inc. (Nasdaq: TRDA), a biotechnology company aiming to transform the lives of patients and become the world's foremost intracellular the...

1 year ago - GlobeNewsWire

Entrada Therapeutics Announces Clinical Hold on IND Application for ENTR-601-44 in Duchenne Muscular Dystrophy

BOSTON, Dec. 19, 2022 (GLOBE NEWSWIRE) -- Entrada Therapeutics, Inc. (Nasdaq: TRDA), a biopharmaceutical company aiming to transform the lives of patients by establishing intracellular Endosomal Escap...

2 years ago - GlobeNewsWire

Entrada Therapeutics shares jump on collaboration with Vertex

Shares of Entrada Therapeutics Inc. TRDA, +3.20% rallied 15% in premarket trading on Thursday after the company announced a deal with Vertex Pharmaceuticals Inc. VRTX, +1.85% that aims to develop trea...

2 years ago - Market Watch

Vertex and Entrada Therapeutics Establish Collaboration to Discover and Develop Endosomal Escape Vehicle (EEV) Therapeutics for Myotonic Dystrophy Type 1 (DM1)

BOSTON--(BUSINESS WIRE)--Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) and Entrada Therapeutics, Inc. (Nasdaq: TRDA) today announced a global collaboration focused on discovering and developing...

Other symbols: VRTX
2 years ago - Business Wire